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Introduction {#sec005}
============

For the control of sexually transmitted infections (STI) timely testing and adequate treatment strategies are essential to prevent adverse health outcomes and reduce or halt transmission. Still many infected people remain untested and untreated \[[@pone.0186722.ref001]--[@pone.0186722.ref003]\]. This may be because they do not attend care or because they are not adequately tested when in care. For example, while STI clinic guidelines recommend regular testing in men who have sex with men (MSM), the reality is that MSM are infrequently tested, only partially tested or not tested at all \[[@pone.0186722.ref004]--[@pone.0186722.ref006]\]. Even, HIV positive MSM may remain hidden to care, because they are not visiting regular (STI) care services and/or STI care is often considered beyond the focus of the HIV practitioner \[[@pone.0186722.ref006], [@pone.0186722.ref007]\]. Further, MSM who contact their GP may not be completely tested, such as would have been the case when they were tested according to STI clinic guidelines (i.e. on human immunodeficiency virus (HIV), syphilis, Hepatitis B virus (HBV), and anorectal and urogenital and/or oropharyngeal *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (NG) \[[@pone.0186722.ref008]\].

To increase STI testing beyond regular STI care, many target group specific interventions have been set up to increase testing behavior in key populations like MSM. These include the use of web based outreach strategies combined with home-collection of screening samples for testing \[[@pone.0186722.ref009]--[@pone.0186722.ref011]\]. It has been shown that self-sampling can be a feasible and effective alternative for key populations that are currently not visiting STI clinics or accessing other regular health care. Self-sampling especially introduced in STI screening programs can be a valuable addition to current STI control \[[@pone.0186722.ref010], [@pone.0186722.ref012]--[@pone.0186722.ref016]\].

Till now self-based testing interventions were mainly focused on CT and NG testing in heterosexual individuals as these samples have been shown to be as easy, acceptable and valid compared to samples taken by a health care provider \[[@pone.0186722.ref012], [@pone.0186722.ref013]\]. However, for screening of HIV, HBV and syphilis, a care provider still needs to draw a venous blood sample hampering home-sampling. Self-taken blood sampling procedures are hardly available in routine STI care settings in industrialized countries. An alternative self-sampling blood test could positively impact efficiency of STI control in MSM. Also in outreach screening and in hard to reach populations in partner testing or enhanced screening of potentially affected contacts during outbreaks for e.g. syphilis self-sampling may be of added value.

A method for self-collected sampling of blood samples, more commonly used in developing countries, is sampling by dried blood spots (DBS) with a finger prick. Blood droplets are absorbed on a filter paper, which subsequently can be sent to a laboratory by regular mail \[[@pone.0186722.ref017]--[@pone.0186722.ref019]\].

Previous studies showed that DBS results for HIV, HBV and syphilis are as reliable as venous blood puncture \[[@pone.0186722.ref017]--[@pone.0186722.ref024]\]. Most studies are, however, performed in settings different from ours, e.g. hospital setting instead of self-collected sampling, different climatic circumstances, so that transport conditions are different.

In this study we assessed the acceptability and feasibility of self-collection of DBS in MSM visiting an STI clinic and we evaluated the performance of DBS for serological screening of HIV, HBV and syphilis compared to blood drawn by venipuncture in our regular routine setting of our STI clinic and HIV and hepatitis outpatient clinic of our hospital. A valid and acceptable alternative for serum could likely have great impact to reach hidden MSM with testing as an addition to regular care.

Methods {#sec006}
=======

Study populations {#sec007}
-----------------

DBS were collected from MSM, visiting the STI clinic of the public health service South Limburg (PHS) and among HIV and/or HBV infected patients, visiting the outpatient clinics for HIV and/or hepatitis of the Maastricht University Medical Centre (MUMC) in the period January 2012---April 2015. In total 217 individuals participated; 183 visited the STI clinic and 34 the outpatient clinics. The participants of the outpatient clinics were included in the study to purposefully increase the number of HIV and HBV positive DBS samples.

Questionnaire about feasibility and acceptability {#sec008}
-------------------------------------------------

The first 93 (51%) MSM who participated in de DBS study, visiting the STI clinic were asked to fill in a questionnaire about the feasibility and acceptability about self-collection of DBS. These individuals were asked to collect the DBS themselves to imitate the sampling situation at home as much as possible. They were provided an instruction scheme with several steps depicted by icons and a clear picture of the DBS card with the 5 circles (cross section 1.5 cm) for sampling. Three completely filled spots were needed to perform 3 tests. The DBS from the other participants were taken by health-care providers to compare self-sampling with sampling by a health care provider. The questionnaire included questions whether they (completely) agreed with statements (5-items) on the experience of self-collection, the instructions for use, the future use of DBS, comparing different care settings and social acceptance.

Routine diagnostics for HIV, Treponema pallidum and HBV {#sec009}
-------------------------------------------------------

HIV Ag/Ab, *Treponema* Ig and HBsAg are essential tests to screen for active infections and used for this purpose in current care. Although the national policy is vaccinating all MSM for HBV not all MSM are fully vaccinated yet and therefore HBsAg screening is included in this study.

Screening for HIV infection is done with a fourth generation screening HIV Ag/Ab test (HIV combi PT, Roche, Basel, Switzerland). The result of the HIV Ag/Ab test gave an index value, which was interpreted as follows: \< 0.9 is negative, \> = 0.9 and \<1.1 is grey zone and \> = 1.1 is positive. Grey zone and positive screening tests were confirmed by an immunoblot (MP diagnostics, Santa Anna, California, USA).

The algorithm for syphilis screening on serum was as follows: For seronegative individuals screening was performed with an anti-Treponemal antibody (*T*. *pallidum* Ig) test (*Treponema pallidum*, Biokit 3.0, Barcelona, Spain). Borderline or positive *T*. *pallidum* Ig tests were confirmed by TPPA (Fujirebio Diagnostic inc. Malvern, PA, USA) and FTA-abs (Trepo-spot IF, Biomerieux, Lyon, France) for confirmation of the syphilis infection and RPR (RPR reditest, Biokit, Barcelona, Spain) to determine stage and activity of infection. Discrepant combination of results were sent to a reference laboratory (National Institute for Public Health and the Environment) for confirmation with immunoblot. The result of the *T*. *pallidum* Ig test was indicated as an index value, which was interpreted as follows: \<0.9 was negative, \> = 0.9 and \<1.1was grey zone and \> = 1.1 was positive.

In routine setting screening for HBV on serum was done with testing HBsAg for active HBV infection (HBsAg II, Roche, Basel, Switzerland). In case of a positive HBsAg test, anti HBc, anti-HBs, HBeAg, and anti-HBe (anti-HBc, anti-HBs II, HBeAg, anti-HBe, Roche, Basel, Switzerland) were additionally determined in serum. If necessary a HBsAg confirmation test was used (Biomerieux, Lyon, France). The result of the HBsAg gave an index value, which was interpreted as follows: For HBsAg \< 0.9 was negative, \> = 0.9 and \<1.1 was grey zone and \> = 1.1 was positive.

The DBS results were compared with the results from routine diagnostic test algorithms. This means that (low) positive screening tests in serum that could not be confirmed in the confirmation assays were interpreted as negative. Thus the conclusive result based on both regular screening test and confirmatory test (gold standard) were used to compare with DBS, which were tested with the screening tests only (i.e. HIV Ag/Ab, *Treponema* Ig and HBsAg). For confirmatory tests following positive screening in DBS a secondary sample (i.e. venous blood) would be required.

Elution from DBS {#sec010}
----------------

DBS were drawn from the 3^rd^ or 4^th^ finger by puncture with a lancet. For this study a card with 5 spots with a diameter of 15 mm should be filled with blood. After taking the DBS the cards were air-dried for at least 10 minutes. The cards were transported to the laboratory within 48 hrs. in sealed bags.

The cards were kept at 4°C until analysis. Analysis was done within 5 days. Eight mm discs were punched and placed into a microtube. Discs for HIV Ag/Ab and HBsAg were eluted in PBS-- 0.5% tween buffer and for *T*. *pallidum* Ig discs were eluted in diluent of the assay (Biokit 3.0, Barcelona, Spain). Two discs were placed in 250 μl buffer and incubated for 1 hour on a rotation table. After centrifuging the eluate was directly used for the tests.

Medical ethical approval {#sec011}
------------------------

The medical ethics committee of the Maastricht University Medical Centre (Maastricht, the Netherlands) approved the study (12-4-040). All participants were asked prior to voluntary participation to give their written informed consent.

Statistical analysis {#sec012}
--------------------

Descriptive statistics were performed using IBM® SPSS Statistics (V.23.0.0, IBM, Somers, New York, USA). Chi-square test was used for comparing self-collected and health care provider collected DBS and coefficient of determination (R^2^) were used for comparing analytical indexes of the test results of DBS and sera.

Results {#sec013}
=======

Study participants {#sec014}
------------------

The median age of the participants (n = 217) was 40 years with a range between 17--80 years. The majority of the participants (202/217, 93%) were of male sex. From the STI clinic 183 MSM participated and from the out-patient clinic 19 men and 15 women.

The DBS contained variable amounts of blood per spot and variable numbers of blood spots were filled (up to five). In 198 (91.2%) of participants 3 spots were sufficiently filled to perform 3 tests. From 5 and 1 participants, respectively 2 and 1 test(s) could be performed due to low amount of blood. Thirteen DBS cards could not be used for testing because the blood volume on the DBS was insufficient for testing. There was no statistically significant difference in self-sampling (n = 88) or sampling by a health care provider (n = 129) in the number of tests that could be performed (Chi^2^ P = 0.73).

Feasibility and acceptability {#sec015}
-----------------------------

Ninety three MSM participants filled in the questionnaire on feasibility and acceptability ([Table 1](#pone.0186722.t001){ref-type="table"}). Notable was that the majority of men agreed that it was clear (84%) and easy (86%) to do the finger-prick, while lower percentages agreed that it was clear and easy to apply the blood onto the card. Also, the majority of men would use the bloodspot test again, but only half mentioned that sending DBS over the postal mail would be fine. Few of these men, who came for a clinic visit and then were confronted with a DBS, stated that they would prefer DBS over clinic visit. Slightly less than half of the men thought that their friends would use DBS and might also prefer home-based sampling over a clinic visit.

10.1371/journal.pone.0186722.t001

###### Acceptance of DBS testing and attitudes towards future use in 93 MSM undergoing DBS test and attending an STI clinic for regular STI care.

![](pone.0186722.t001){#pone.0186722.t001g}

  Instructions and experience of use                                                                 (completely) agree [\*](#t001fn002){ref-type="table-fn"}
  -------------------------------------------------------------------------------------------------- ----------------------------------------------------------
  It is clear how to do the finger-prick                                                             84.2% (n = 80)
  It is easy to do the finger-prick                                                                  86.3% (n = 82)
  How to apply the blood on the card is clear                                                        69.5% (n = 66)
  To apply the blood on the card is easy                                                             53.7 (n = 51)
  It is unpleasant to do the finger-prick                                                            26.3% (n = 25)
  **Future use**                                                                                      
  A bloodspot test is a good initiative                                                              57.9% (n = 55)
  I would do the bloodspot test again                                                                80.0% (n = 76)
  To send my bloodspot over the postal mail is fine with me                                          50.5% (48)
  A test result by email or text message is acceptable                                               89.5% (85)
  **Comparing care-settings**                                                                         
  I prefer a finger-prick over blood drawing by a clinic nurse                                       8.4% (n = 8)
  I prefer to do an STI test at home than to come to the STI clinic                                  15.8% (n = 15)
  A personal talk with a professional nurse is more important to me than able to do a test at home   81.1% (n = 77)
  **Social acceptance**                                                                               
  I think that my friends find an STI test with a bloodspot by the Internet a good initiative        49.5% (n = 47)
  I think that my friends would use the blood spot test at their home                                41.1% (n = 39)
  I think my friends would prefer to do an STI test at home than to come to the STI clinic           47.4% (n = 45)

Acceptance of DBS testing and attitudes towards future use in 93 MSM undergoing DBS test and attending an STI clinic for regular STI care.

\*score 1 and 2 on likert scale 1--5 (completely agree to completely disagree)

Comparison of DBS and routine diagnostics {#sec016}
-----------------------------------------

For validity of DBS analysis we tested 195 DBS-serum pairs for HIV Ag/Ab, 191 for *T*. *pallidum* Ig and 202 DBS-serum pairs for HBsAg. HIV Ag/Ab showed a 100% sensitivity and specificity ([Table 2](#pone.0186722.t002){ref-type="table"}). For *T*. *pallidum* Ig the sensitivity was 90% with specificity of 99%. The sensitivity for HBsAg was respectively 90% with specificity of 99%.

10.1371/journal.pone.0186722.t002

###### Test results of DBS-serum pairs of the validation study.

![](pone.0186722.t002){#pone.0186722.t002g}

   Test                    No. of samples tested   No. samples positive in DBS and serum   No. samples negative in DBS and serum   Sensi-tivity   95%CI; upper and lower limit of sensitivity   Speci-ficity   95% CI; upper and lower limit of specificity
  ------------------------ ----------------------- --------------------------------------- --------------------------------------- -------------- --------------------------------------------- -------------- ----------------------------------------------
  **HIV Ag/Ab**            195                     38                                      157                                     100%           81%-100%                                      100%           97%-100%
  ***T*. *pallidum* Ig**   191                     26                                      160                                     90%            72%-97%                                       99%            95%-100%
  **HBsAg**                202                     17                                      183                                     90%            71%-100%                                      99%            97%-100%

Number of DBS-serum pairs tested and test results of the validation study (95%CI--95% confidence interval).

Discrepancy analysis {#sec017}
--------------------

In total 7 (1.2%) out of 588 DBS-serum pairs tested showed a different result in DBS and serum. No discrepant results were observed for HIV Ag/Ab. For *T*. *pallidum* Ig 3 infections were false negative in DBS and 2 borderline false positive in DBS. For HBsAg, 2 discrepant results were found; one false positive in DBS and one false negative in DBS. ([Table 3](#pone.0186722.t003){ref-type="table"}).

10.1371/journal.pone.0186722.t003

###### Analysis of discrepant results in DBS and serum.

![](pone.0186722.t003){#pone.0186722.t003g}

   Test                    No. of samples tested   No. of discrepant results   Discrepancy in    Conclusion
  ------------------------ ----------------------- --------------------------- ----------------- --------------------------------------------------------------------------------------
  ***T*. *pallidum* Ig**   191                     3                           DBS − / serum +   false negative in DBS: confirmation of lues infection with positive TPPA and FTA-Abs
                                                   2                           DBS + / serum −   borderline false positive in DBS; serum was negative
  **HBsAg**                202                     1                           DBS − / serum +   HBsAg = 2.2 in serum: chronic HBV carrier in reconvalescence phase
                                                   1                           DBS + / serum −   false positive HBsAg = 1.17 index in DBS

Analysis of discrepant results in DBS and serum.

Index values in DBS and serum {#sec018}
-----------------------------

Index values for HIV Ag/Ab, *T*. *pallidum* Ig and HBsAg were compared between DBS and serum ([Fig 1](#pone.0186722.g001){ref-type="fig"}). For HIV Ag/Ab and HBsAg a clear distinction between positive and negative results was shown (R^2^ were respectively, 0.92 and 0.90 for HIV Ag/Ab and HBsAg). For *T*. *pallidum* Ig this distinction was less clear, since the number of false negatives in DBS were higher, compared to the HIV and HBsAg index values (see previous paragraph) (R^2^ was 0.75 for *T*. *pallidum* Ig).

![Scatterplots of the index values measured in DBS and serum.\
Scatterplots of the index values measured in DBS and serum. 2a. shows the log transformed results for HIV Ag/Ab, 2b. the results for *T*. *pallidum* Ig 2c. the log transformed results for HBsAg.](pone.0186722.g001){#pone.0186722.g001}

HIV positive participants {#sec019}
-------------------------

In total 38 HIV positive participants were included. Test performance appeared similar in HIV positives with sensitivities of 92% and 100% respectively for *T*. *pallidum* Ig and HBsAg and specificities of 100% for the both tests, although confidence intervals were wide ([Table 4](#pone.0186722.t004){ref-type="table"}).

10.1371/journal.pone.0186722.t004

###### Subgroup analysis of DBS-serum pairs in HIV positive participants.

![](pone.0186722.t004){#pone.0186722.t004g}

   Test                    No. of samples tested   No. of samples positive in DBS and serum   No. of samples negative in DBS and serum   Sensi-tivity   95% CI; upper and lower limit of sensitivity   Speci-ficity   95% CI; upper and lower limit of specificity
  ------------------------ ----------------------- ------------------------------------------ ------------------------------------------ -------------- ---------------------------------------------- -------------- ----------------------------------------------
  ***T*. *pallidum* Ig**   36                      12                                         24                                         92%            74--100%                                       100%           79%--100%
  **HBsAg**                38                      1                                          37                                         100%           3%--100%                                       100%           91%--100%

Subgroup analysis of DBS-serum pairs in HIV positive participants (95% CI--95% confidence interval).

Discussion {#sec020}
==========

This study shows that DBS as method for sampling is a valid alternative for venous blood puncture with high sensitivity (\>90%) and specificity (\>99%) for HIV Ag/Ab, *Treponema pallidum* Ig and HBsAg. DBS is also found acceptable in MSM in our study. To a large extent DBS proved to be likely feasible in routine use since overall 91% of the DBS was adequately taken to perform the three screening tests. Also, there was no difference in the quality of DBS taken by self-sampling compared to DBS taken by a health care provider This makes self-collected sampling with DBS (in combination with additional genital and anorectal CT and NG testing) a feasible approach to reach part of the hidden MSM. It could therefore be a valuable addition to regular care and also could be used for outreach settings \[[@pone.0186722.ref016], [@pone.0186722.ref025]\].

This study is not without limitations. In 70% of the participants who filled in the questionnaire the method was clear and they would do DBS again. Nevertheless, acceptability was measured in a selection of MSM (possibly overestimating acceptance) who attended the STI clinic (possibly underestimation of acceptance as they already came to a clinic and already had received care by a professional). Although we included patients from the HIV and hepatitis out-patient clinics to artificially increase the number of positives analyses, the numbers were still rather small (between 17 and 38), possibly limiting the precision in the sensitivities estimated. Other studies also studied cohorts with various numbers of positives (between 10 to 204) \[[@pone.0186722.ref019], [@pone.0186722.ref020], [@pone.0186722.ref022], [@pone.0186722.ref024], [@pone.0186722.ref026]\]. Further, we have small numbers for subgroup analysis, such as analyses by HIV status.

The quality of DBS may be subject to interobserver bias because the DBS were visually screened before preparation of the eluate. However, we expect this to be a small bias and therefore of minor influence on our results.

HIV Ag/Ab in DBS showed a sensitivity and specificity of 100%. Comparison of the index values in DBS and serum show a good correlation. Similar results were found in other studies showing sensitivities of 100% and specificities of 99.5%-100% in DBS despite the fact that different elution protocols and screening assays were used in these studies \[[@pone.0186722.ref019], [@pone.0186722.ref020], [@pone.0186722.ref022], [@pone.0186722.ref023]\].

*T*. *pallidum* Ig in DBS in this study showed a sensitivity of 90% with a specificity of 99%. Smit et al. found a sensitivity (94%) with EIA syphilis screening \[[@pone.0186722.ref026]\]. They found, however, a low specificity of 50%, which may be due to increased non-specific binding in the assay, because they used a longer incubation time.

HBsAg showed acceptable sensitivity of 90% and specificity of 99%. Other studies showed sensitivities of 96--98% and specificities of 100% \[[@pone.0186722.ref017], [@pone.0186722.ref020], [@pone.0186722.ref022], [@pone.0186722.ref024]\]. Our study showed a slightly lower sensitivity because one low positive HBsAg (index of 2.2) was missed in DBS. This serum was from a chronic HBV carrier in the period of seroconversion from positive to negative. These and other data indicate that the lower detection limit is increased in DBS and low positive levels of HBsAg levels in serum may be missed in DBS \[[@pone.0186722.ref022]\]. However, this should be no problem in routine screening for active HBV infection (either acute or chronic HBV), because it has been shown that HBsAg levels in chronically HBV infected persons are usually above 100 IU/ml, which can be detected by DBS \[[@pone.0186722.ref027]--[@pone.0186722.ref029]\]. This is in line with the results of our other HBsAg positive participants ([Fig 1](#pone.0186722.g001){ref-type="fig"}).

Several factors should be taken into account to implement DBS as method for sampling. Successful implementation would for example be dependent on whether users understand how to apply the blood samples on the paper and how willing they would be to send the DBS by postal mail. The actual application in care however still needs to be assessed, such as in our ongoing intervention study called PacMan. Although there is room for improving the instructions for taking DBS, the results in this study with respect to the acceptability and feasibility was overall adequate. In 91% of the DBS 3 tests could be performed. One study with a response rate of 90% showed that for HIV screening with DBS 99% of the DBS were adequately taken by self-collection \[[@pone.0186722.ref030]\]. Yet, in our study 9% were inadequately taken DBS and instructions can be optimized to improve this further.

To be able to implement DBS in routine setting it is also important that storage and transport conditions do not influence the test results. In routine use it will take up to 3 days before DBS will arrive at the laboratory when DBS are home-collected and sent to the laboratory by regular mail. For HIV Ag/Ab and HBsAg storage conditions have been assessed for stability at room temperature up to 200 days \[[@pone.0186722.ref018], [@pone.0186722.ref019], [@pone.0186722.ref024]\]. DBS were stable at room temperature for at least one week until 4 weeks \[[@pone.0186722.ref018], [@pone.0186722.ref019], [@pone.0186722.ref024]\]. For implementation in routine setting the storage at room temperature does not exceed one week, if DBS are directly sent to the laboratory. Thus, it is not expected that sending DBS by regular mail would harm the test results and it is the most convenient way of transportation of DBS to the laboratory.

In conclusion, DBS as method for self-sampling at home is a valid and likely acceptable alternative for venous blood puncture for STI screening in MSM. It was also feasible to iuse in addition to in routine STI clinic care. The next step is to implement DBS as method for home-collected sampling in combination with self-collection of swabs and/or urine for *CT* and *NG* screening in order to better reach the hidden MSM with STI testing and treatment.
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